Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -88.19% | 57.39% | 57.60% | 16.15% | -26.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -88.19% | 57.39% | 57.60% | 16.15% | -26.52% |
| Cost of Revenue | -8.34% | 18.33% | 11.03% | 1.41% | -517.07% |
| Gross Profit | 0.17% | -8.32% | 19.35% | 7.63% | 1,060.73% |
| SG&A Expenses | 727.19% | 24.34% | 15.46% | -109.93% | 1,389.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 270.09% | 21.44% | 13.19% | -45.16% | 88.49% |
| Operating Income | -357.47% | -17.54% | -1.92% | 62.55% | -204.91% |
| Income Before Tax | -261.31% | -30.76% | -1.40% | 39.09% | 9.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -261.31% | -30.76% | -1.40% | 39.09% | 9.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -261.31% | -30.76% | -1.40% | 39.09% | 9.46% |
| EBIT | -357.47% | -17.54% | -1.92% | 62.55% | -204.91% |
| EBITDA | -359.43% | -17.60% | -1.92% | 62.74% | -207.53% |
| EPS Basic | -256.25% | -33.33% | 0.00% | 40.00% | 5.88% |
| Normalized Basic EPS | -337.50% | -20.00% | -10.00% | 54.55% | -166.67% |
| EPS Diluted | -256.25% | -33.33% | 0.00% | 40.00% | 5.88% |
| Normalized Diluted EPS | -337.50% | -20.00% | -10.00% | 54.55% | -166.67% |
| Average Basic Shares Outstanding | 0.18% | 0.09% | 0.01% | 0.01% | 0.01% |
| Average Diluted Shares Outstanding | 0.18% | 0.09% | 0.01% | 0.01% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |